$2500 | Single User
$5000 | Site License
$7500 | Global License

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

Published by Global Data: 01 Feb 2018 | 224124 | In Stock

Introduction

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

Summary

This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas -

- Current or anticipated future use of sarilumab in RA

- Current use of tocilizumab in RA

- Expected future change to sarilumab & tocilizumab use

- Comparison of sarilumab & tocilizumab clinical profile in RA

- Non-clinical differentiating factors between sarilumab & tocilizumab

- Impact of and factors contributing to sirukumab discontinuation in RA

- IL-6 inhibitors vs. JAK inhibitors in RA

- KOL awareness of olokizumab currently in development for RA

Key Highlights

- Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs

- Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients

- In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.

Scope

- The briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents
for KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

  • Table of Contents

    Executive Summary

    Background

    Research Panel Composition

    Results & Implications

    Appendix

Additional Details

Publisher

Global Data

Publisher Information

Reference

224124 | GDHC010SP

Number of Pages

29

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
KOL Perspectives: Adaptive Trial Designs in IBD
KOL Perspectives: Adaptive Trial Designs in IBDSummaryThis KOL Insight briefing focuses on KOLs view...
22 Aug 2018 by Global Data USD $2,500 More Info
Biosimilars: European Payer Perspectives (2016)
IntroductionWhat’s driving the uptake of biosimilars in Europe and what still needs to be done?The E...
01 Jan 2016 by FirstWord Pharma USD $2,195 More Info
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeho...
30 Nov 2015 by La Merie USD $500 More Info
Biosimilars: US Payer Perspectives
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
01 Apr 2015 by FirstWord Pharma USD $2,195 More Info
Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
01 Apr 2015 by FirstWord Pharma USD $695 More Info
Payer Perspectives on Risk Sharing Deals
IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
01 Mar 2015 by FirstWord Pharma USD $695 More Info
Biosimilars: European Payer Perspectives
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
06 Jan 2015 by FirstWord Pharma USD $2,195 More Info
Patient Assistance Programs: Payer and Pharma Perspectives
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
02 Oct 2014 by FirstWord Pharma USD $695 More Info
Oncology Market Access Europe – Payer and Industry Perspectives
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
03 Jul 2014 by FirstWord Pharma USD $995 More Info
Stakeholder Perspectives: Innovation within the Biopharma Industry
IntroductionWhat does innovation mean within the biopharma industry? How much you spend on R&D? How ...
19 Feb 2014 by FirstWord Pharma USD $2,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data